Previous 10 | Next 10 |
vTv Therapeutics (VTVT) slumps 38% after-hours after announcing that its Phase 2 Elevage study of azeliragon in people with mild Alzheimer’s disease and type 2 diabetes did not meet its primary objective of demonstrating an improvement in cognition relative to placebo.The tra...
HIGH POINT, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that the Phase 2 Elevage study of azeliragon in people with mild Alzheimer’s disease and type 2 diabetes did not meet its primary objective of demonstrating an improvement...
Aditum Bio Announces Formation of Third Company, Anteris Bio OAKLAND, Calif. , Dec. 15, 2020 /PRNewswire/ -- Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedi...
Hot Penny Stocks To Watch Today When it comes to finding quality penny stocks to watch, anyone with the right information at hand can do it. Creating a list of stocks might be easy, finding which ones might have the most value can be a little more time-intensive. But, the great thin...
Prevail Therapeutics (PRVL) +84% on being acquired by Lilly for ~$1.04B.OncoCyte Corporation (OCX) +63% after company enters agreement with Burning Rock Biotech.Anavex Life Sciences (AVXL) +40% as it's blarcamesine successful in mid-stage rett syndrome study.Mid-Con Energy Part...
vTv Therapeutics (VTVT) gains 11% premarket after entering into a licensing agreement with Anteris Bio for worldwide rights to its novel Nrf2 activator compound, HPP971 to be developed as a new therapy for renal disease. Under the terms of agreement, vTv will receive an upfront...
HIGH POINT, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC (“vTv”) has entered into a licensing agreement with Anteris Bio for worldwide rights to vTv’s novel clinical-stage Nrf2 activator compou...
Gainers: Sonoma Pharmaceuticals (SNOA) +87%.aTyr Pharma (LIFE) +65%.NantHealth (NH) +63%.vTv Therapeutics (VTVT) +55%.Equus Total Return (EQS) +45%Hancock Jaffe Laboratories (HJLI) +34%.MDJM (MDJH) +25%.Foresight Autonomous (FRSX) +23%.Solid Biosciences (SLDB) +22%.22...
Gainers: Sonoma Pharmaceuticals (SNOA) +114%. NantHealth (NH) +110%. vTv Therapeutics (VTVT) +59%. aTyr Pharma (LIFE) +33%. NantKwest (NK) +22%.Losers: SELLAS Life Sciences (SLS) -33%. Immutep (IMMP) -29%. Salarius Pharmaceuticals (SLRX) -29%. Nabriva Therapeutics (NBRV) -29%. ALX O...
vTv Therapeutics (VTVT) inked a common stock purchase agreement for up to $47M with Chicago-based institutional investor Lincoln Park Capital Fund; optionality to sell the shares over a 3-year period.Net proceeds from the transaction to be used for general corporate purposes and to suppo...
News, Short Squeeze, Breakout and More Instantly...
vTv Therapeutics Inc. Company Name:
VTVT Stock Symbol:
NASDAQ Market:
vTv Therapeutics Inc. Website:
HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has pla...
2024-06-26 16:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1D Cadisegliatin has been dosed in over ...